Compare Abeona Therapeutics Inc (ABEO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JetBlue Airways Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while JetBlue Airways Corporation trades at $5.57 (market cap $2.13B). The key difference: JetBlue Airways Corporation is far larger — about 5.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | JBLU | |
|---|---|---|
Market Cap | $373.32M | $2.13B |
Sector | Health | Industrials |
52-Week High | $7.23 | $6.46 |
52-Week Low | $4.17 | $4.03 |
Enterprise Value | $228.22M | $9.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JetBlue (JBLU) trades at $5.72, down 4.98% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The airline faces fundamental challenges with negative net income margins (-7.78%) and ROE (-33.51%) despite a low P/S ratio of 0.24. Recent strategic shifts include expanding premium Mint service in Fort Lauderdale while reducing New York operations to cut costs.
The outlook remains cautious with Wall Street showing limited conviction (19% buy rating) and a consensus price target of $5.12 below current levels. Key risks include persistent losses, high debt levels (debt-to-asset ratio over 50%), and competitive pressures, though lower fuel costs and travel demand provide some sector support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
